Frankfurt - Delayed Quote EUR
Thiogenesis Therapeutics, Corp. (Q8M.F)
0.3840
-0.0260
(-6.34%)
At close: May 2 at 9:59:02 AM GMT+2
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Patrice P. Rioux M.D., Ph.D. | Co-Founder, CEO & Director | 167.47k | -- | 1951 |
| Mr. Brook G. Riggins C.F.A. | CFO, Secretary & Director | 141.94k | -- | 1966 |
| Ms. Mary Jo Bagger | Consultant for Clinical Operations | -- | -- | -- |
Thiogenesis Therapeutics, Corp.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Thiogenesis Therapeutics, Corp., a biopharmaceutical company, develops thiol-active therapeutic compounds to treat unmet pediatric medical needs. The company's lead product candidate comprises TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke, other mitochondrial diseases, Rett syndrome, and pediatric non-alcoholic fatty liver diseases. Thiogenesis Therapeutics, Corp. is headquartered in Toronto, Canada.
Corporate Governance
Thiogenesis Therapeutics, Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 22, 2025 at 10:59 AM UTC - May 26, 2025 at 12:00 PM UTC
Thiogenesis Therapeutics, Corp. Earnings Date
Recent Events
Recent Events Information Not Available
Related Tickers
NEUP Neuphoria Therapeutics Inc.
5.06
+1.10%
PMVP PMV Pharmaceuticals, Inc.
0.9966
-0.34%
EPIX ESSA Pharma Inc.
1.7300
-2.26%
IKNA Ikena Oncology, Inc.
1.2500
+2.46%
HLVX HilleVax, Inc.
1.9600
+1.55%
ATXS Astria Therapeutics, Inc.
5.36
+3.88%
KZR Kezar Life Sciences, Inc.
4.5000
+2.27%
GLTO Galecto, Inc.
2.9900
-1.64%
NERV Minerva Neurosciences, Inc.
1.7000
-2.30%
ANTX AN2 Therapeutics, Inc.
1.2200
-1.61%